Vabysmo SmPC: Uses, Mechanism, Safety and FAQs
Quick summary: Vabysmo (faricimab) is an eye injection used for certain retinal conditions, including neovascular age-related macular degeneration and diabetic macular edema. It works by targeting both Ang-2 and VEGF-A pathways. This page gives...
This content is for educational purposes only and does not replace medical advice, diagnosis or treatment from a qualified healthcare professional.
Quick summary: Vabysmo (faricimab) is an eye injection used for certain retinal conditions, including neovascular age-related macular degeneration and diabetic macular edema. It works by targeting both Ang-2 and VEGF-A pathways.
This page gives a plain-English overview of the SmPC, including uses, mechanism, safety points and common questions.
Medical disclaimer: This article is for general information only and does not replace the official SmPC, patient leaflet, or advice from a qualified eye specialist, doctor or pharmacist. Always check the latest official product information for full details.
What is Vabysmo 120 mg/mL solution for injection?
Vabysmo contains faricimab and is given as an intravitreal injection, meaning it is injected into the eye by a qualified healthcare professional.
It is used for certain retinal diseases where abnormal blood vessel activity and leakage can affect vision.
What conditions is Vabysmo used for?
Based on the content provided, Vabysmo is used for:
- Neovascular age-related macular degeneration (nAMD)
- Diabetic macular edema (DMO)
- Retinal vein occlusion (RVO)
These conditions can lead to vision loss or blurred vision, so treatment and follow-up are important.
How does Vabysmo work?
Vabysmo is described as a bispecific IgG1 antibody. It targets two pathways involved in eye disease:
- Angiopoietin-2 (Ang-2) — involved in vascular stability and leakage
- VEGF-A — involved in abnormal blood vessel growth and increased permeability
By acting on both pathways, Vabysmo is intended to help reduce leakage and support retinal health.
What does the SmPC say about dosage?
The original content states that dosing is given by healthcare professionals and may vary depending on the eye condition and response to treatment.
Because dosing schedules can change, readers should always confirm the exact regimen in the official SmPC or with the treating clinic. Do not rely on general summaries for injection timing or dose decisions.
| Topic | What the article says |
|---|---|
| Medicine | Vabysmo (faricimab) |
| Form | 120 mg/mL solution for injection |
| Route | Intravitreal injection |
| Main targets | Ang-2 and VEGF-A |
What side effects are mentioned?
The content provided mentions the following possible side effects:
- Increased intraocular pressure
- Eye pain or discomfort
- Conjunctival hemorrhage
It also mentions arterial thromboembolic events as a serious risk that requires monitoring.
For the full and most up-to-date safety information, readers should check the official product leaflet and speak with a healthcare professional.
What are the contraindications mentioned?
The original content lists the following situations:
- Active ocular infections
- History of severe hypersensitivity to any component of the formulation
- Severe systemic diseases that may increase the risk of complications from intravitreal injections
Because contraindications can be updated, the official SmPC should always be checked before treatment decisions are made.
How does Vabysmo compare with other treatments?
The source content says Vabysmo has shown comparable efficacy to aflibercept and Lucentis (ranibizumab) in clinical studies.
It also notes that Vabysmo’s dual action on Ang-2 and VEGF-A may be a distinguishing feature compared with treatments that target VEGF alone.
Choice of treatment depends on the individual patient, the eye condition being treated, and the clinician’s assessment.
What is Vabysmo made of?
Vabysmo contains faricimab as the active ingredient. The original content also notes that the formulation includes inactive excipients that help with stability and delivery.
For a full ingredient list, the official SmPC or package leaflet should be consulted.
What should patients verify with a doctor or pharmacist?
If you are reading the SmPC for general understanding, it can help to confirm:
- Which eye condition Vabysmo is being used for
- The planned injection schedule
- Any eye symptoms that need urgent review
- Whether any allergies or eye infections are relevant before treatment
- Where to find the latest official leaflet or SmPC
FAQs about Vabysmo
▸ What is Vabysmo used for?
The content provided says Vabysmo is used for neovascular age-related macular degeneration, diabetic macular edema and retinal vein occlusion.
▸ How does Vabysmo work in the eye?
It targets Ang-2 and VEGF-A, two pathways involved in abnormal blood vessel activity and leakage in retinal disease.
▸ What side effects are mentioned in the article?
The article mentions increased intraocular pressure, eye pain or discomfort, conjunctival hemorrhage and arterial thromboembolic events.
▸ Is Vabysmo the same as faricimab?
Yes. Faricimab is the active ingredient in Vabysmo.
▸ Where can I check the official dosing information?
The official SmPC and patient leaflet are the best sources for the latest dosing and administration details.
▸ Is this article a substitute for medical advice?
No. It is a general summary and should not replace advice from an eye specialist or the official product information.
Safety reminder: Eye injections should only be given by trained healthcare professionals. If you have new eye pain, sudden vision changes, signs of infection, or any unusual symptoms after treatment, seek medical advice promptly.
Sources and further reading
For the most reliable information, use the official product documents and trusted medicines references.
Medical disclaimer
This content is for educational purposes only. It should not be used as a substitute for professional medical advice, diagnosis or treatment. Always ask a doctor, pharmacist or qualified healthcare professional before starting, stopping or changing any medicine.
Sources and verification
The following sources or official references are listed to support verification of the medicine information discussed in this article.
Medicine information can change and may vary depending on country, product formulation, patient history and professional guidance. Always check official medicine information and ask a healthcare professional for personal medical questions.